{"id":4634,"date":"2021-07-02T16:40:44","date_gmt":"2021-07-02T13:40:44","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=4634"},"modified":"2021-07-02T17:10:53","modified_gmt":"2021-07-02T14:10:53","slug":"ucuncu-doz-ve-hastaligi-gecirenlerde-covid-19-asisi-uygulamalariyla-ilgili-sorulariniza-yanitlar","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/ucuncu-doz-ve-hastaligi-gecirenlerde-covid-19-asisi-uygulamalariyla-ilgili-sorulariniza-yanitlar\/","title":{"rendered":"\u00dc\u00e7\u00fcnc\u00fc Doz ve Hastal\u0131\u011f\u0131 Ge\u00e7irenlerde COVID-19 A\u015f\u0131s\u0131 Uygulamalar\u0131yla \u0130lgili Sorular\u0131n\u0131za Yan\u0131tlar"},"content":{"rendered":"

\u00dc\u00e7\u00fcnc\u00fc doz a\u015f\u0131 karar\u0131n\u0131 vermek i\u00e7in antikorlar\u0131ma bakt\u0131rmal\u0131 m\u0131y\u0131m?<\/strong><\/span><\/p>\n

Hay\u0131r. Mevcut antikor testleri ile belirlenen seviyelerin hangi de\u011ferden itibaren ve ne kadar s\u00fcre koruyucu oldu\u011fu bilinememektedir. Ayr\u0131ca testlerden kaynaklanan nedenlerle yalanc\u0131 olarak pozitif sonu\u00e7 da \u00e7\u0131kabilmektedir. Bu nedenle a\u015f\u0131 olmak veya olmamak karar\u0131 i\u00e7in antikorlar\u0131n\u0131za bakt\u0131rman\u0131za gerek yoktur.<\/p>\n

\u0130ki doz BioNTech\u00ae a\u015f\u0131s\u0131 oldum. Ne zaman 3. doz a\u015f\u0131y\u0131 olmal\u0131y\u0131m?<\/strong><\/span><\/p>\n

\u015eimdiki veriler BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n olu\u015fturdu\u011fu ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n g\u00fc\u00e7l\u00fc bir \u015fekilde 9-12 ay devam etti\u011fini g\u00f6sterdi\u011finden 2 doz BioNTech\u00ae olan ki\u015filerin 9-12 ay boyunca ek doz a\u015f\u0131 olmalar\u0131na gerek yoktur. Bu ki\u015filerde 3. doz a\u015f\u0131ya ihtiya\u00e7 olup olmayaca\u011f\u0131 ve ne zaman olaca\u011f\u0131 bu konuda yap\u0131lmakta olan \u00e7al\u0131\u015fmalar\u0131n sonu\u00e7lar\u0131na ve ortaya \u00e7\u0131kabilecek yeni varyantlara g\u00f6re belli olacakt\u0131r. Sadece BioNTech\u00ae bulunan \u00fclkelerde 2 doz uygulanmaktad\u0131r.<\/p>\n

\u0130ki doz Sinovac\u00ae a\u015f\u0131s\u0131 oldum. Ne zaman 3. doz a\u015f\u0131y\u0131 olmal\u0131y\u0131m? Hangi a\u015f\u0131y\u0131 olmal\u0131y\u0131m?<\/strong><\/span><\/p>\n

\u0130ki doz Sinovac\u00ae a\u015f\u0131s\u0131 olan ki\u015filerde olu\u015fan ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n 3-6 ay i\u00e7erisinde giderek azald\u0131\u011f\u0131 g\u00f6zlenmektedir. Ayr\u0131ca Sinovac\u00ae a\u015f\u0131s\u0131n\u0131n t\u00fcm d\u00fcnyada birka\u00e7 ay i\u00e7inde hakim hale gelmesi beklenen Delta varyant\u0131na kar\u015f\u0131 etkisi de s\u0131n\u0131rl\u0131 g\u00f6z\u00fckmektedir. Bu nedenlerle iki doz Sinovac\u00ae a\u015f\u0131s\u0131 olanlar\u0131n ikinci dozdan 3-6 ay sonra 3. doz (hat\u0131rlatma veya rapel) a\u015f\u0131y\u0131 olmas\u0131 hem kendilerinin korunmas\u0131 hem de Delta varyant\u0131n\u0131n yay\u0131lmas\u0131n\u0131n \u00f6nlenmesi a\u00e7\u0131s\u0131ndan ak\u0131lc\u0131 olacakt\u0131r.<\/p>\n

Bu ki\u015filerde 3. doz a\u015f\u0131 Sinovac\u00ae ile uygulanabilir. Ancak Delta varyant\u0131na kar\u015f\u0131 koruyuculu\u011fu sa\u011flamak a\u00e7\u0131s\u0131ndan, \u00f6zellikle sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131, kalabal\u0131k yerlerde \u00e7al\u0131\u015fanlar gibi vir\u00fcsle kar\u015f\u0131la\u015fma olas\u0131l\u0131\u011f\u0131 y\u00fcksek ki\u015filerin, ayr\u0131ca daha g\u00fc\u00e7l\u00fc ba\u011f\u0131\u015f\u0131kl\u0131k olu\u015fturdu\u011fu i\u00e7in ileri ya\u015ftaki ki\u015filer ve ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olanlar\u0131n 3. doz a\u015f\u0131y\u0131 BioNTech\u00ae ile olmas\u0131 tercih edilmelidir.<\/p>\n

BioNTech\u00ae a\u015f\u0131s\u0131 ileri ya\u015ftaki ki\u015filerde daha \u00e7ok yan etki yap\u0131yor mu?<\/strong><\/span><\/p>\n

BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n yan etkileri ya\u015f ilerledik\u00e7e azalmakta buna kar\u015f\u0131n koruyuculu\u011funda ise \u00f6nemli bir de\u011fi\u015fiklik olmamaktad\u0131r. Sinovac\u00ae a\u015f\u0131s\u0131n\u0131n koruyuculu\u011fu ileri ya\u015ftaki ki\u015filerde azald\u0131\u011f\u0131ndan ileri ya\u015f grubunda \u00fclkemizdeki a\u015f\u0131lardan BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n uygulanmas\u0131 \u00f6nerilir.<\/p>\n

Hastal\u0131\u011f\u0131 ge\u00e7irmi\u015f olan ki\u015filerin a\u015f\u0131lanmas\u0131 gerekli mi? Ne zaman a\u015f\u0131lans\u0131nlar? <\/strong><\/span><\/p>\n

Bug\u00fcne kadarki bilimsel veriler hastal\u0131\u011f\u0131 belirtili olarak ge\u00e7iren ki\u015filerde ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131n yakla\u015f\u0131k 6-12 ay devam etti\u011fini g\u00f6stermekle birlikte zamanla koruyuculu\u011fun azalmas\u0131 s\u00f6z konusu oldu\u011fundan hastal\u0131\u011f\u0131 ge\u00e7iren ki\u015filerin 3-6 aydan itibaren a\u015f\u0131lanabilecekleri d\u00fc\u015f\u00fcn\u00fclmektedir.<\/p>\n

Hastal\u0131\u011f\u0131 ge\u00e7irmi\u015f olanlar hangi a\u015f\u0131yla a\u015f\u0131lans\u0131nlar?<\/strong><\/span><\/p>\n

Hastal\u0131\u011f\u0131 ge\u00e7irmi\u015f olan ki\u015filere 3-6. aydan itibaren tek doz BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n uygulanmas\u0131 ile y\u00fcksek d\u00fczeyde ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015ftu\u011funu g\u00f6steren \u00e7al\u0131\u015fmalar bulunmaktad\u0131r. Daha az say\u0131da veri olmakla birlikte hastal\u0131\u011f\u0131 ge\u00e7irmi\u015f olan ki\u015filere iki doz olmak kayd\u0131yla Sinovac\u00ae a\u015f\u0131s\u0131 uygulamas\u0131n\u0131n da y\u00fcksek d\u00fczeyde ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flad\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir. Bu konuda kesin \u00f6neride bulunmak i\u00e7in hastal\u0131\u011f\u0131 ge\u00e7irenlere tek doz BioNTech\u00ae veya iki doz Sinovac\u00ae uygulamalar\u0131ndan hangisinin daha faydal\u0131 olaca\u011f\u0131n\u0131 ara\u015ft\u0131ran \u00e7al\u0131\u015fma sonu\u00e7lar\u0131na ihtiya\u00e7 vard\u0131r. Ancak eldeki verilerle Delta varyant\u0131n\u0131n yay\u0131lmas\u0131n\u0131n \u00f6nlenmesi ve yeni varyantlar\u0131n ortaya \u00e7\u0131kmas\u0131n\u0131n engellenebilmesi i\u00e7in hastal\u0131\u011f\u0131 ge\u00e7irenlere 3-6 ay sonra BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n uygulanmas\u0131 daha ak\u0131lc\u0131 g\u00f6r\u00fcnmektedir.<\/p>\n

\u0130ki doz a\u015f\u0131dan sonra COVID ge\u00e7irdim. \u00dc\u00e7\u00fcnc\u00fc doz a\u015f\u0131m\u0131 ne zaman olmal\u0131y\u0131m?<\/strong><\/span><\/p>\n

Bir veya iki doz sonras\u0131nda COVID ge\u00e7iren ki\u015filer t\u0131pk\u0131 a\u015f\u0131lanmam\u0131\u015f ve COVID ge\u00e7irmi\u015f ki\u015filer gibi hastal\u0131ktan sonra 3-6. aydan itibaren a\u015f\u0131lanabilecekleri d\u00fc\u015f\u00fcn\u00fclmektedir. Bir doz Sinovac\u00ae a\u015f\u0131s\u0131ndan sonra COVID ge\u00e7irmi\u015f olanlar\u0131n 3-6. aydan itibaren olacaklar\u0131 a\u015f\u0131 birinci dozla ayn\u0131 a\u015f\u0131 olabilece\u011fi gibi hem kendilerinin korunmas\u0131 hem de Delta varyant\u0131n\u0131n yay\u0131lmas\u0131n\u0131n \u00f6nlenmesi ve yeni varyantlar\u0131n ortaya \u00e7\u0131kmas\u0131n\u0131n engellenebilmesi a\u00e7\u0131s\u0131ndan BioNTech\u00ae a\u015f\u0131s\u0131 olmalar\u0131 do\u011fru olacakt\u0131r.<\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

\u00dc\u00e7\u00fcnc\u00fc doz a\u015f\u0131 karar\u0131n\u0131 vermek i\u00e7in antikorlar\u0131ma bakt\u0131rmal\u0131 m\u0131y\u0131m? Hay\u0131r. Mevcut antikor testleri ile belirlenen seviyelerin hangi de\u011ferden itibaren ve ne kadar s\u00fcre koruyucu oldu\u011fu bilinememektedir. Ayr\u0131ca testlerden kaynaklanan nedenlerle yalanc\u0131 olarak pozitif sonu\u00e7 da \u00e7\u0131kabilmektedir. Bu nedenle a\u015f\u0131 olmak veya olmamak karar\u0131 i\u00e7in antikorlar\u0131n\u0131za bakt\u0131rman\u0131za gerek yoktur. \u0130ki doz BioNTech\u00ae a\u015f\u0131s\u0131 oldum. Ne zaman 3. doz a\u015f\u0131y\u0131 olmal\u0131y\u0131m? \u015eimdiki veriler BioNTech\u00ae a\u015f\u0131s\u0131n\u0131n olu\u015fturdu\u011fu ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n g\u00fc\u00e7l\u00fc bir \u015fekilde 9-12 ay devam etti\u011fini g\u00f6sterdi\u011finden 2 doz BioNTech\u00ae olan ki\u015filerin 9-12 ay boyunca ek doz a\u015f\u0131 olmalar\u0131na gerek yoktur. Bu ki\u015filerde 3. doz a\u015f\u0131ya ihtiya\u00e7 olup olmayaca\u011f\u0131 ve ne zaman olaca\u011f\u0131 […]<\/p>\n","protected":false},"author":4,"featured_media":4635,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/4634"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=4634"}],"version-history":[{"count":3,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/4634\/revisions"}],"predecessor-version":[{"id":4638,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/4634\/revisions\/4638"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/4635"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=4634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=4634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=4634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}